Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 6
2004 7
2005 1
2006 8
2007 6
2008 6
2009 7
2010 8
2011 10
2012 5
2013 9
2014 14
2015 16
2016 9
2017 9
2018 3
2019 10
2020 16
2021 20
2022 7
2023 7
2024 13
2025 16
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Saji H, et al. Among authors: yamaguchi m. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. Lancet. 2022. PMID: 35461558 Clinical Trial.
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: yamaguchi m. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Among authors: yamaguchi m. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Takamori S, Haratake N, Bhattacharya A, Kikutake C, Ozawa H, Shigeta K, Nakashoji A, Isozaki H, Shimokawa M, Suyama M, Hashinokuchi A, Takada K, Toyokawa G, Yamada Y, Takenaka T, Taguchi K, Yamaguchi M, Yoshizumi T, Hata AN, Kufe D. Takamori S, et al. Among authors: yamaguchi m. Signal Transduct Target Ther. 2025 Nov 28;10(1):389. doi: 10.1038/s41392-025-02482-7. Signal Transduct Target Ther. 2025. PMID: 41309558 Free PMC article.
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K; West Japan Oncology Group (WJOG). Tachihara M, et al. Among authors: yamaguchi m. JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309. JAMA Oncol. 2023. PMID: 37676681 Free PMC article. Clinical Trial.
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
Zenke Y, Niho S, Toi Y, Yamaguchi M, Hara S, Akazawa Y, Hosomi Y, Yonesaka K, Akamatsu H, Yokoyama T, Tanizaki J, Ueno K, Gyotoku H, Misumi T, Nakagawa K, Yamamoto N, Tsuboi M. Zenke Y, et al. Among authors: yamaguchi m. Lung Cancer. 2025 Aug;206:108633. doi: 10.1016/j.lungcan.2025.108633. Epub 2025 Jun 23. Lung Cancer. 2025. PMID: 40602204 Clinical Trial.
[Interstitial pneumonitis].
Hirai F, Toyokawa G, Ohba T, Kitajima H, Yamaguchi M, Maruyama R, Hamatake M, Seto T, Sugio K, Ichinose Y. Hirai F, et al. Among authors: yamaguchi m. Gan To Kagaku Ryoho. 2011 Nov;38(11):1782-4. Gan To Kagaku Ryoho. 2011. PMID: 22083185 Japanese.
A protocol for a Japanese prospective cohort evaluating the features of patients with uncontrolled asthma achieving clinical remission: J-CIRCLE.
Tanabe N, Hara Y, Shimizu K, Marumo S, Miyata J, Morita K, Watanabe T, Oishi K, Yamaguchi M, Asai K, Nakano Y, Hirano T, Matsunaga K, Koya T, Matsumoto H, Fukunaga K, Konno S, Kaneko T, Hirai T. Tanabe N, et al. Among authors: yamaguchi m. Respir Investig. 2024 Nov;62(6):1209-1214. doi: 10.1016/j.resinv.2024.10.009. Epub 2024 Nov 4. Respir Investig. 2024. PMID: 39500243
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).
Yoshioka H, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, Goto Y, Shimizu J, Miyauchi E, Yoshino I, Misumi T, Watanabe Y, Hata A, Kisohara A, Kuyama S, Yamaguchi M, Miwa A, Iwasawa S, Tanaka M, Gemma A. Yoshioka H, et al. Among authors: yamaguchi m. Cancer Sci. 2026 Mar;117(3):727-738. doi: 10.1111/cas.70242. Epub 2025 Dec 11. Cancer Sci. 2026. PMID: 41378717 Free PMC article.
197 results